poisar

Stocks · News reference

Oculis Doses First PIONEER-1 Patient As Privosegtor Advances Into Registrational Testing For Optic Neuritis With FDA SPA Agreement

Benzinga Newsdesk
More stocks newsConnected markets

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OCS
Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. Zacks.Com

    Strength Seen in Halozyme Therapeutics (HALO): Can Its 3.3% Jump Turn into More Strength?

    Halozyme Therapeutics shares rose 3.3% to $115.13 on strong volume, driven by investor optimism around its ENHANZE drug-delivery technology collaborations with major pharmaceutical companies. The company is expected to report quarterly earnings of $2.25 per share (+30.8% YoY) and revenues of $470.95 million (+32.9% YoY). With a 2.6% upward revision in consensus EPS estimates over the past 30 days and a Zacks Rank #2 (Buy) rating, analysts suggest monitoring the stock for potential continued strength.

    HALOOCSOCSAW